vs

Side-by-side financial comparison of Dayforce (DAY) and GLOBUS MEDICAL INC (GMED). Click either name above to swap in a different company.

GLOBUS MEDICAL INC is the larger business by last-quarter revenue ($826.4M vs $481.6M, roughly 1.7× Dayforce). GLOBUS MEDICAL INC runs the higher net margin — 17.0% vs -40.9%, a 57.9% gap on every dollar of revenue. On growth, GLOBUS MEDICAL INC posted the faster year-over-year revenue change (25.7% vs 9.5%). Over the past eight quarters, GLOBUS MEDICAL INC's revenue compounded faster (16.7% CAGR vs 9.8%).

Dayforce, Inc., formerly Ceridian, is an American human resources software and services company.

Globus Medical, Inc. is a publicly traded orthopedic medical device company headquartered in Audubon, Pennsylvania, United States. Globus is focused on the design, development, and commercialization of products that enable surgeons to promote healing in patients with musculoskeletal disorders.

DAY vs GMED — Head-to-Head

Bigger by revenue
GMED
GMED
1.7× larger
GMED
$826.4M
$481.6M
DAY
Growing faster (revenue YoY)
GMED
GMED
+16.3% gap
GMED
25.7%
9.5%
DAY
Higher net margin
GMED
GMED
57.9% more per $
GMED
17.0%
-40.9%
DAY
Faster 2-yr revenue CAGR
GMED
GMED
Annualised
GMED
16.7%
9.8%
DAY

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
DAY
DAY
GMED
GMED
Revenue
$481.6M
$826.4M
Net Profit
$-196.8M
$140.6M
Gross Margin
68.4%
Operating Margin
6.3%
20.5%
Net Margin
-40.9%
17.0%
Revenue YoY
9.5%
25.7%
Net Profit YoY
-9940.0%
430.4%
EPS (diluted)
$-1.23
$1.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DAY
DAY
GMED
GMED
Q4 25
$826.4M
Q3 25
$481.6M
$769.0M
Q2 25
$464.7M
$745.3M
Q1 25
$481.8M
$598.1M
Q4 24
$465.2M
$657.3M
Q3 24
$440.0M
$625.7M
Q2 24
$423.3M
$629.7M
Q1 24
$431.5M
$606.7M
Net Profit
DAY
DAY
GMED
GMED
Q4 25
$140.6M
Q3 25
$-196.8M
$119.0M
Q2 25
$21.3M
$202.8M
Q1 25
$14.9M
$75.5M
Q4 24
$10.8M
$26.5M
Q3 24
$2.0M
$51.8M
Q2 24
$-1.8M
$31.8M
Q1 24
$7.1M
$-7.1M
Gross Margin
DAY
DAY
GMED
GMED
Q4 25
68.4%
Q3 25
67.2%
Q2 25
66.6%
Q1 25
67.3%
Q4 24
47.0%
59.9%
Q3 24
45.8%
56.8%
Q2 24
44.1%
58.7%
Q1 24
47.6%
60.2%
Operating Margin
DAY
DAY
GMED
GMED
Q4 25
20.5%
Q3 25
6.3%
17.9%
Q2 25
9.1%
10.2%
Q1 25
6.4%
16.2%
Q4 24
6.1%
9.2%
Q3 24
4.7%
7.7%
Q2 24
3.3%
7.9%
Q1 24
9.4%
1.3%
Net Margin
DAY
DAY
GMED
GMED
Q4 25
17.0%
Q3 25
-40.9%
15.5%
Q2 25
4.6%
27.2%
Q1 25
3.1%
12.6%
Q4 24
2.3%
4.0%
Q3 24
0.5%
8.3%
Q2 24
-0.4%
5.0%
Q1 24
1.6%
-1.2%
EPS (diluted)
DAY
DAY
GMED
GMED
Q4 25
$1.01
Q3 25
$-1.23
$0.88
Q2 25
$0.13
$1.49
Q1 25
$0.09
$0.54
Q4 24
$0.07
$0.19
Q3 24
$0.01
$0.38
Q2 24
$-0.01
$0.23
Q1 24
$0.04
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DAY
DAY
GMED
GMED
Cash + ST InvestmentsLiquidity on hand
$627.6M
$557.2M
Total DebtLower is stronger
$631.1M
Stockholders' EquityBook value
$2.7B
$4.6B
Total Assets
$8.7B
$5.3B
Debt / EquityLower = less leverage
0.23×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DAY
DAY
GMED
GMED
Q4 25
$557.2M
Q3 25
$627.6M
$18.8M
Q2 25
$625.2M
Q1 25
$557.3M
Q4 24
$579.7M
$890.1M
Q3 24
$494.1M
$71.9M
Q2 24
$465.4M
$82.5M
Q1 24
$392.5M
$80.4M
Total Debt
DAY
DAY
GMED
GMED
Q4 25
Q3 25
$631.1M
Q2 25
$631.8M
Q1 25
$632.4M
Q4 24
$1.2B
Q3 24
$1.2B
Q2 24
$1.2B
Q1 24
$1.2B
Stockholders' Equity
DAY
DAY
GMED
GMED
Q4 25
$4.6B
Q3 25
$2.7B
$4.4B
Q2 25
$2.7B
$4.3B
Q1 25
$2.6B
$4.1B
Q4 24
$2.5B
$4.2B
Q3 24
$2.6B
$4.1B
Q2 24
$2.5B
$4.0B
Q1 24
$2.4B
$3.9B
Total Assets
DAY
DAY
GMED
GMED
Q4 25
$5.3B
Q3 25
$8.7B
$5.1B
Q2 25
$8.5B
$5.0B
Q1 25
$9.5B
$4.7B
Q4 24
$9.1B
$5.3B
Q3 24
$8.1B
$5.1B
Q2 24
$9.0B
$5.0B
Q1 24
$10.8B
$4.9B
Debt / Equity
DAY
DAY
GMED
GMED
Q4 25
Q3 25
0.23×
Q2 25
0.23×
Q1 25
0.24×
Q4 24
0.47×
Q3 24
0.47×
Q2 24
0.49×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DAY
DAY
GMED
GMED
Operating Cash FlowLast quarter
$31.2M
$248.6M
Free Cash FlowOCF − Capex
$202.4M
FCF MarginFCF / Revenue
24.5%
Capex IntensityCapex / Revenue
5.6%
Cash ConversionOCF / Net Profit
1.77×
TTM Free Cash FlowTrailing 4 quarters
$588.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DAY
DAY
GMED
GMED
Q4 25
$248.6M
Q3 25
$31.2M
$249.7M
Q2 25
$112.7M
$77.9M
Q1 25
$49.6M
$177.3M
Q4 24
$81.0M
$210.3M
Q3 24
$91.8M
$203.7M
Q2 24
$99.2M
$54.3M
Q1 24
$9.1M
$52.4M
Free Cash Flow
DAY
DAY
GMED
GMED
Q4 25
$202.4M
Q3 25
$213.9M
Q2 25
$31.3M
Q1 25
$141.2M
Q4 24
$193.2M
Q3 24
$161.7M
Q2 24
$26.5M
Q1 24
$23.8M
FCF Margin
DAY
DAY
GMED
GMED
Q4 25
24.5%
Q3 25
27.8%
Q2 25
4.2%
Q1 25
23.6%
Q4 24
29.4%
Q3 24
25.8%
Q2 24
4.2%
Q1 24
3.9%
Capex Intensity
DAY
DAY
GMED
GMED
Q4 25
5.6%
Q3 25
4.7%
Q2 25
6.2%
Q1 25
6.0%
Q4 24
2.6%
Q3 24
6.7%
Q2 24
4.4%
Q1 24
4.7%
Cash Conversion
DAY
DAY
GMED
GMED
Q4 25
1.77×
Q3 25
2.10×
Q2 25
5.29×
0.38×
Q1 25
3.33×
2.35×
Q4 24
7.50×
7.94×
Q3 24
45.90×
3.93×
Q2 24
1.71×
Q1 24
1.28×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DAY
DAY

Dayforce Recurring$333.0M69%
Cloud And Bureau Professional Services And Other$78.5M16%
Float$42.2M9%
Powerpay Recurring$19.7M4%
Other Recurring$8.2M2%

GMED
GMED

Other$391.8M47%
Nevro Merger Agreement$293.6M36%
Enabling Technologies$141.0M17%

Related Comparisons